These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19100499)

  • 1. Severe sirolimus-related inflammatory state anemia in an HIV+ liver transplant patient with calcineurin inhibitor renal insufficiency: a case report.
    Moreno A; Bárcena R; García-Gonzalez M; García-Hoz F; Quereda C; Casado JL; Pérez-Elías MJ; Fortún J; Nuño J; Arranz I; Moreno S
    Transplant Proc; 2008 Dec; 40(10):3810-2. PubMed ID: 19100499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
    Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors.
    Di Benedetto F; Di Sandro S; De Ruvo N; Spaggiari M; Montalti R; Ballarin R; Cappelli G; Gerunda GE
    J Clin Gastroenterol; 2009 Mar; 43(3):280-6. PubMed ID: 19057397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients.
    Nair S; Eason J; Loss G
    Liver Transpl; 2003 Feb; 9(2):126-9. PubMed ID: 12548505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients.
    Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Barrientos A
    Transplant Proc; 2007 Sep; 39(7):2242-4. PubMed ID: 17889151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of Sirolimus in five pediatric patients undergoing solid organ transplantation].
    Roque E J; Ríos M G; Vignolo A P; Pinochet V C; Schultz M; Humeres A R; Delucchi A; Rius A M; Hepp K J
    Rev Med Chil; 2008 May; 136(5):631-6. PubMed ID: 18769812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function.
    Friend P; Russ G; Oberbauer R; Murgia MG; Tufveson G; Chapman J; Blancho G; Mota A; Grandaliano G; Campistol JM; Brault Y; Burke JT;
    Transpl Int; 2007 Sep; 20(9):754-60. PubMed ID: 17565578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in erythropoietin resistance after conversion from sirolimus to enteric coated mycophenolate sodium.
    Augustine JJ; Rodriguez V; Padiyar A; Bodziak KA; Schulak JA; Hricik DE
    Transplantation; 2008 Aug; 86(4):548-53. PubMed ID: 18724224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation.
    Campbell MS; Rai J; Kozin E; Bloom RD; Markmann JF; Olthoff KM; Shaked A; Rajender Reddy K
    Clin Transplant; 2007; 21(3):377-84. PubMed ID: 17488388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients.
    Morard I; Dumortier J; Spahr L; Hadengue A; Majno P; Morel P; Mentha G; Giostra E
    Liver Transpl; 2007 May; 13(5):658-64. PubMed ID: 17457887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus therapy in liver transplant patients: an initial experience at a single center.
    Nocera A; Andorno E; Tagliamacco A; Morelli N; Bottino G; Ravazzoni F; Casaccia M; Barocci S; Alice S; Santori G; Ghirelli R; Valente U
    Transplant Proc; 2008; 40(6):1950-2. PubMed ID: 18675098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaemia, microcytosis and sirolimus--is iron the missing link?
    Sofroniadou S; Kassimatis T; Goldsmith D
    Nephrol Dial Transplant; 2010 May; 25(5):1667-75. PubMed ID: 20054028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state.
    Thaunat O; Beaumont C; Chatenoud L; Lechaton S; Mamzer-Bruneel MF; Varet B; Kreis H; Morelon E
    Transplantation; 2005 Nov; 80(9):1212-9. PubMed ID: 16314788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus monotherapy in liver transplantation.
    Di Benedetto F; Di Sandro S; De Ruvo N; Masetti M; Montalti R; Romano A; Guerrini GP; Ballarin R; De Blasiis MG; Gerunda GE
    Transplant Proc; 2007; 39(6):1930-2. PubMed ID: 17692656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is sirolimus responsible for proteinuria?
    Dervaux T; Caillard S; Meyer C; Ellero B; Woehl-Jaegle ML; Hannedouche T; Wolf P; Moulin B
    Transplant Proc; 2005; 37(6):2828-9. PubMed ID: 16182822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of everolimus monotherapy on hematological parameters and iron homeostasis in de novo liver transplant recipients: preliminary results.
    Masetti M; Rompianesi G; Montalti R; Romano A; Spaggiari M; Ballarin R; Guerrini GP; Gerunda GE
    Transplant Proc; 2008; 40(6):1947-9. PubMed ID: 18675097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus interferes with iron homeostasis in renal transplant recipients.
    Maiorano A; Stallone G; Schena A; Infante B; Pontrelli P; Schena FP; Grandaliano G
    Transplantation; 2006 Oct; 82(7):908-12. PubMed ID: 17038905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.